Eye Catching Stock News: Stealth BioTherapeutics Corp (NASDAQ: MITO)

 Stealth BioTherapeutics Corp (NASDAQ: MITO) changed -1.69% to recent value of $8.75. The stock transacted 204 shares during most recent day however it has an average volume of 6.51K shares. It spotted trading -58.31% off 52-week high price. On the other end, the stock has been noted 2.34% away from the low price over the last 52-weeks.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced the appointment of Robert Weiskopf as Chief Financial Officer (CFO).

“We’re delighted to welcome Rob to our team during this pivotal time in our growth trajectory,” said Chief Executive Officer Reenie McCarthy. “As we approach Phase 3 data in primary mitochondrial myopathy, engage in key regulatory interactions on Barth syndrome and continue to expand upon our new product pipeline, Rob’s wealth and breadth of financial experience will enhance our ability to execute our mission of developing therapies for patients suffering from serious mitochondrial diseases.”

As CFO, Weiskopf will oversee a disciplined financial planning and growth strategy as Stealth prepares for the potential launch of elamipretide and advances its pipeline programs. Pivotal data is expected for the Company’s lead product candidate, elamipretide, in primary mitochondrial myopathy in early 2020 and newly announced product candidate, SBT-272, is poised to enter the clinic by year-end 2019.

“I’m inspired by Stealth’s patient-focused mission,” said Mr. Weiskopf. “I see tremendous promise in elamipretide’s potential to improve the lives of patients suffering from rare mitochondrial diseases for which there are no approved therapies, and look forward to helping the team develop and implement strategies to fund these important efforts.”

 MITO earnings per share (EPS) expected to touch remained -16.60% for this year .

 The company has 34.99M of outstanding shares and 5.41M shares were floated in the market. According to the most recent quarter its current ratio was 2.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -21.82% from the mean of 20 days, -25.82% from mean of 50 days SMA and performed -31.93% from mean of 200 days price. Company’s performance for the week was -11.62%, -31.21% for month and YTD performance remained -26.47%.

Leave a Reply

Your email address will not be published. Required fields are marked *